HealthDay - Abilify Approved for Adolescents With Schizophrenia
The U.S. Food and Drug Administration has approved the Bristol-Myers Squibb antipsychotic drug Abilify (aripiprazole) for adolescents aged 13 to 17 diagnosed with schizophrenia, the company said Tuesday.
Related Results
Some developmentally disabled see benefits from aripiprazole.(care and treatm…
U.S. Food and Drug Administration Approves ABILIFY for Add-On Treatmen…
U.S. Food and Drug Administration Approves ABILIFY for the Acute Treat…
The antipsychotic market is worth an estimated $10.7 billion and is led by El…
Otsuka Pharmaceutical to Ship Antipsychotic Agent
The FDA first approved the drug to treat schizophrenia in adults in November 2002. More than 12.5 million U.S. prescriptions for the medication have since been written, …
Read the full article with a Free Trial at MyWire.
